CanBas Co., Ltd.
Stock Price Chart
2026/08/12 UpdatedPrice Trend
2026/08/12 UpdatedPrice & Trading Details
2026/08/12 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/09 UpdatedNo financial data available
Latest IR Information
-
Please ensure to extract the formal title listed in the PDF and use it as is. Do not generate or modify the title on your own
There are many unknowns, but it appears to be a materials introducing business plans and organizational structure, with no specific settlement-related figures verifiable from the excerpt. It is not definitively known whether earnings information exists.
Read more -
Financial Summary for the Year Ending June 2026 (Japanese GAAP) (Consolidated)
For the year ended June 2026, operating loss was 1,358 million yen, ordinary loss was 1,307 million yen, and net loss attributable to owners of the parent was 1,308 million yen. R&D expenses increased, with CBP501-related costs as the main...
Read more -
Notice regarding Schedule of Recording Non-operating Income
Recognized foreign exchange gain of 7,570 thousand yen as non-operating income. Cumulative for the fourth quarter amounts to a foreign exchange gain of 46,449 thousand yen recorded as non-operating income. This matter is reflected in the June 2026 period Financial...
Read more -
Notice Regarding Full-Year Earnings Forecast for the Fiscal Year Ending June 2026
Read more
Latest News (5 items)
Company Information
About
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
